News & Events

Finding the right CMC advisor can become difficult when development timelines are tight, technical information is distributed across manufacturers, laboratories and internal teams, and decisions made today can affect the quality dossier later in the product lifecycle. Companies may have strong scientific expertise in-house, but still lack the capacity to coordinate CMC inputs, prepare submission-ready… View Article …

For biotech companies, Medical Affairs can become a pressure point long before a full internal function is in place. As clinical programmes advance, evidence expands and launch planning begins, teams may suddenly need scientific communication, stakeholder engagement, medical education and medical information capabilities at the same time. The right medical affairs consultant can help close… View Article …

A company may have extensive regulatory documentation in place and still not have a clear answer to a critical question: where does the current regulatory position fall short of what is actually required? Differences can exist between approved information, supporting documentation, implemented changes, authority commitments and current regulatory expectations. In this context, experienced regulatory affairs… View Article …

Rare disease companies bringing a new therapy to market face a distinct medical education challenge: awareness of the disease itself may still be limited. Healthcare professionals may encounter only a small number of affected patients, symptoms can overlap with more common conditions, and diagnosis may depend on recognising when specialist referral or further testing is… View Article …

In oncology, the educational challenge is rarely a lack of information. The greater problem is timing: new biomarkers, indications, combination regimens and treatment sequences can alter clinical questions faster than a conventional education plan can be updated. For pharmaceutical and biotech teams, oncology medical education therefore has to remain aligned with a treatment landscape that… View Article …

A veterinary PSMF may appear to be a documentation requirement, but preparing one that is complete, internally consistent and ready for regulatory scrutiny requires much more than filling predefined sections. Information must be collected from across the wider veterinary pharmacovigilance system, verified against current practice and presented in a way that clearly demonstrates how the… View Article …

Advanced therapy medicinal products (ATMPs) combine complex science with manufacturing processes that can continue to evolve throughout clinical development. For developers, the challenge is not only producing a consistent product, but building a quality strategy that can support changing process knowledge, analytical capability and future regulatory expectations. This is where experienced regulatory affairs consulting can… View Article …

For biotech companies developing innovative therapies, communication with regulatory authorities can influence key development decisions. Yet limited internal regulatory resources, complex scientific questions and evolving evidence can make these interactions difficult to prepare and manage. This is where experienced biotech regulatory consulting can provide valuable support. When regulatory questions are poorly framed, scientific positions are… View Article …

Pharmaceutical Medical Affairs teams are expected to deliver scientifically rigorous, relevant and engaging education while managing increasingly complex evidence, multiple stakeholders and demanding timelines. Yet when specialist expertise or additional capacity is needed, expanding the delivery structure does not always solve the problem. What teams often need is an experienced medical education specialist who can… View Article …

Medicine shortages are becoming an increasingly important challenge for pharmaceutical companies across the EU, with potential consequences for continuity of supply, regulatory compliance and, most importantly, patient care. Supply chain vulnerabilities, manufacturing and quality issues, unexpected changes in demand or limited alternatives can all contribute to disruptions that may ultimately affect medicine availability. For Marketing… View Article …

Veterinary pharmacovigilance can quickly become resource-intensive as companies work to maintain continuous oversight of veterinary product safety. Marketing authorisation holders must ensure appropriate pharmacovigilance expertise and keep their systems compliant, even when internal teams are already stretched or specialist veterinary PV resources are limited. For companies that need additional expertise or capacity, a large CRO… View Article …

Pharmaceutical Medical Affairs teams are expected to deliver scientifically credible, relevant and compliant education while managing increasingly complex evidence, diverse healthcare professional needs and multiple communication channels. At the same time, limited internal capacity and demanding timelines can make it difficult to translate scientific objectives into consistent, high-quality educational programmes, making the right medical education… View Article …

Understanding the patient journey from the first symptoms to diagnosis, treatment, and long-term disease management is essential for pharmaceutical companies developing truly patient-centric strategies. Yet patient journey barriers are rarely uniform. Diagnostic delays, referral gaps, limited treatment access, fragmented care, adherence challenges, and unmet information needs can occur at very different stages depending on the… View Article …

Veterinary pharmaceutical companies operate in an environment where maintaining product safety requires continuous oversight and specialised expertise. Effective veterinary pharmacovigilance requires marketing authorisation holders to maintain appropriate pharmacovigilance systems, continuously monitor product safety, manage safety information, maintain relevant documentation, and ensure that regulatory responsibilities are fulfilled throughout the lifecycle of veterinary medicinal products. As portfolios… View Article …

Bringing a pharmaceutical product to market requires far more than generating strong scientific data. Companies must navigate complex regulatory requirements, coordinate documentation across multiple functions, meet strict submission timelines, respond to health authority questions, and maintain compliance after approval. Without the right regulatory oversight, even relatively small gaps can lead to incomplete submissions, additional authority… View Article …

Preparing a regulatory submission involves much more than compiling documents into the correct structure. Successful eCTD publishing requires precise dossier assembly, technically compliant XML backbones, accurate life cycle operations, and a thorough understanding of regional regulatory requirements. As regulatory authorities continue to advance electronic submission standards and the industry prepares for broader adoption of eCTD… View Article …

Every pharmaceutical company collects enormous amounts of data. Electronic health records, claims databases, patient support programs, Medical Affairs activities, market research, and real-world evidence all generate valuable insights every day. Yet despite this wealth of information, many organizations still struggle to answer fundamental questions: Why are patients diagnosed too late? Where do they discontinue treatment?… View Article …

Developing a successful payer strategy has become far more complex than demonstrating clinical efficacy alone. Today’s reimbursement decisions increasingly depend on whether pharmaceutical companies can clearly demonstrate real-world value, address unmet needs, and show how their therapy improves outcomes across the entire care pathway. An effective payer strategy should be built around real-world patient experiences… View Article …